Background Psoriasis impairs quality of life, but it is unknown whether psoriasis is also an independent risk factor for depression. Objectives To evaluate the incidence and risk of new and recurrent depression in patients with psoriasis. Methods We used individual-level linkage of Danish administrative registers. Patients with psoriasis aged ≥ 18 years between 1 January 1997 and 31 December 2016 were matched 1 : 1 with individuals without psoriasis. Incidence rates were calculated and adjusted hazard ratios (HRs) estimated by Cox regression. Results There were 247 755 patients with psoriasis: 220 721 were treated with topicals (mild psoriasis), 24 771 with systemic nonbiologics (moderate psoriasis) and 2263 with biological therapy (severe psoriasis). The same number of matched referents without psoriasis were also analysed. During a maximum 20 years of follow-up, 45 641 patients with psoriasis and 36 299 referents developed depression. In adjusted models, the HRs (95% confidence interval) of depression were 1Á19 (1Á17-1Á20), 1Á19 (1Á15-1Á23) and 1Á50 (1Á23-1Á84) for mild, moderate and severe psoriasis, respectively. The highest risk was observed among patients with severe psoriasis aged 40-50 years. Concurrent inflammatory bowel disease, but not psoriatic arthritis, was associated with increased risk of depression. The incidence of depression was markedly higher among patients with previous depression. Conclusions Psoriasis was independently associated with risk of depression. These results may help clinicians identify particularly high-risk individuals.
• Psoriasis negatively affects quality of life and confers significant morbidity.
What does this study add?
• Patients with psoriasis, especially those qualifying for biological therapy and aged 40-50 years, have a significantly increased risk of depression.
Psoriasis is a chronic, inflammatory and often stigmatizing skin condition affecting more than 125 million people worldwide. 1 The burden of psoriasis is considerable, and the negative impact of psoriasis on patients' functioning has been reported to be greater than for other medical conditions such as diabetes and heart failure. 2 While psoriasis itself may impact quality of life, for example measured by the Dermatology Life Quality Index (DLQI), numerous studies have also associated psoriasis with the presence of medical comorbidities, including psoriatic arthritis (PsA), inflammatory bowel disease (IBD), diabetes and cardiovascular disease. [3] [4] [5] [6] Patients with psoriasis have an increased incidence and prevalence of depression; 7, 8 however, the question of whether psoriasis itself represents an independent risk factor for depression remains controversial. [9] [10] [11] We therefore examined the risk of new and recurrent depression (or symptoms of depression) in patients with psoriasis in a population-based cohort study.
Patients and methods

Data sources and study population
Denmark has a unique network of administrative and healthcare registries. 12 These can be linked at the individual level to provide virtually complete information on the entire population from cradle to grave, including (but not limited to) data on vital statistics, medical conditions and treatment thereof, education and income. [12] [13] [14] [15] [16] In Denmark, the taxsupported healthcare system gives all residents equal and universal access to healthcare services, including general practitioners and hospitals. Among Danish adults (≥ 18 years) alive and resident in Denmark between 1 January 1997 and 31 December 2016 we identified all patients with recorded psoriasis. The patients were followed (study start) from the first recorded occurrence of psoriasis or their 18th birthday, whichever came last, until the first of either 31 December 2016, death, migration or the occurrence of an end point. Each patient was matched on birth date and sex with one individual from the general population. The index date (study start date) for the matched individuals was the same as for the corresponding patient with psoriasis.
Patients were classified as having psoriasis if they had received a diagnosis of psoriasis or had been treated with pharmacotherapy where the reason for the prescription was specified as psoriasis (e.g. if a patient received methotrexate where the indication was listed as 'for treatment of psoriasis'). The primary end point was the first occurrence of depression, defined by either a diagnosis of depression by a physician or psychologist, or by initiation of treatment with antidepressant drugs if the drug was prescribed for treatment of depression. The relevant codes used for this study are available in Table S1 (see Supporting Information). The Strengthening the Reporting of Observational Studies in Epidemiology recommendations were used for the conduct and reporting of this study. 17 
Statistical analysis
Descriptive characteristics were presented as means and SDs for continuous variables and frequencies and percentages for categorical variables. Patients with psoriasis were categorized according to use of psoriasis-specific therapy in the following groups: (i) topical treatment; (ii) systemic nonbiological treatment; and (iii) biological treatment (or apremilast, as use of this drug in Denmark is restricted to patients qualifying for biological treatment). To ensure the accuracy of this severity classification, only treatments prescribed for cutaneous psoriasis were used. Consequently, if patients received treatment with methotrexate for PsA, for example, rather than for cutaneous psoriasis, this was not included. SAS statistical software version 9Á4 (SAS Institute Inc., Cary, NC, U.S.A.) and Stata software version 13Á0 (StataCorp, College Station, TX, U.S.A.) were used to summarize incidence rates (IRs) per 1000 person-years, and we used Cox regression models to calculate hazard ratios (HRs) for the risk of depression. This method is generally considered a powerful tool in detecting disease and treatment effects in large cohorts. 18 The incidence of depression during follow-up was calculated for: (i) all individuals; (ii) individuals without a history of depression at any time prior to study start; and (iii) individuals with a history of depression, where the last recorded code was a minimum of 3 years prior to the index date (to ensure that any depression occurring during follow-up was in fact a new case of depression). HRs for depression were calculated as fully adjusted, in which age, sex, socioeconomic status, smoking, alcohol abuse, PsA, IBD, hypertension, diabetes and hyperlipidaemia (defined by use of cholesterol-lowering drugs) were considered. These potential confounders were chosen a priori.
Although it has become more infrequent since the introduction of systemic (in particular biological) treatment modalities, Danish patients still require inpatient hospital admission for treatment of their psoriasis (e.g. with coal tar), in case of severe flares or for treatment of pustular psoriasis. These patients may represent a particular subgroup of patients with different characteristics and risk profiles. Consequently, we performed subanalyses in which we assessed the risk of depression in patients following inpatient hospitalization due to psoriasis, while controlling for age, sex, socioeconomic status, smoking, alcohol abuse, PsA, IBD, hypertension, diabetes and hyperlipidaemia, as well as use of topical, systemic nonbiological and biological therapy.
The model assumptions were tested and found to be valid. All statistical tests were conducted using a level of significance of 0Á05, and the results were reported with 95% confidence intervals (CIs), where applicable.
Results
The study cohort comprised a total of 247 755 patients with psoriasis and the same number of matched individuals without psoriasis from the general population. There was a slight female predominance in all groups, except for patients receiving biological therapy, where 65Á0% of patients were men (Table 1) . At baseline, the mean age was markedly lower among patients who were treated with biologics during the study. Smoking (18Á5-24Á1% vs. 14Á3%) and alcohol abuse (8Á4-10Á3% vs. 6Á6%) were more frequent among patients with psoriasis than in the general population. Medical comorbidity was generally more frequent among patients with psoriasis than in the reference group without psoriasis (Table 1) .
During the maximum 20 years of follow-up, 46 641 (18Á8%) and 36 299 (14Á7%) individuals had a recorded episode of depression, among patients with psoriasis and the general population, respectively. Of these, 17 001 (36Á5%) and 14 605 (40Á2%), respectively, did not have a history of depression prior to the start of the study (i.e. first-time depression). Overall, the IRs of depression per 1000 personyears were lowest for patients treated with biologics, although this group was also somewhat younger. The IRs (per 1000 person-years) of first-time depression were 12Á6 (95% CI 12Á4-12Á8), 13Á0 (95% CI 12Á4-13Á6) and 11Á5 (95% CI 9Á2-14Á5) among patients with psoriasis treated with topical therapy, systemic nonbiological therapy and biological therapy, respectively, compared with 10Á5 (95% CI 10Á3-10Á7) in the general population. Across all groups, IRs of depression were markedly higher among patients with a history of previous depression (Table S2 ; see Supporting Information). Specific IRs for patients with psoriasis without PsA are shown in Table S3 (see Supporting Information).
Risk of any depression
In fully adjusted models, increasing age, female sex, smoking, alcohol abuse, low socioeconomic status and medical comorbidity were associated with a significantly increased risk of depression. Among patients with psoriasis, risk of depression was increased among patients receiving topical (adjusted HR 1Á19, 95% CI 1Á17-1Á20), systemic (adjusted HR 1Á19, 95% CI 1Á15-1Á23) and biological therapy (adjusted HR 1Á50, 95% CI 1Á23-1Á84). Notably, while comorbidities such as IBD (adjusted HR 1Á30, 95% CI 1Á23-1Á37) and diabetes (adjusted HR 1Á24, 95% CI 1Á21-1Á27) were associated with a significant risk of depression, concurrent PsA was not associated with an increased risk of depression (adjusted HR 1Á01, 95% CI 0Á96-1Á06) (Table S4 ; see Supporting Information). In age-specific strata, the highest risk of depression was observed among biologic-treated patients aged 40-50 years (adjusted HR 2Á25, 95% CI 1Á57-3Á22) (Fig. 1) .
Risk of first-time depression
Patients with psoriasis receiving topical treatment had a slightly increased risk of first-time depression (adjusted HR 1Á13, 95% CI 1Á11-1Á16), as did patients who received systemic nonbiological psoriasis therapy (adjusted HR 1Á16, 95% CI 1Á10-1Á21) and patients on biological therapy (adjusted HR 1Á30, 95% CI 1Á04-1Á64). Among this cohort, the presence of PsA was associated with a slightly increased risk of first-time depression (adjusted HR 1Á10, 95% CI 1Á02-1Á17), whereas the risk associated with other conditions including hypertension, diabetes and IBD was somewhat higher, albeit still lower than for risk factors such as smoking and alcohol abuse (Table S4 ; see Supporting Information).
Risk of recurrent depression
Among patients with a history of prior depression (i.e. those perceived to be particularly vulnerable), the risk of recurrent depression was not increased among patients treated with topical therapy (adjusted HR 1Á00, 95% CI 0Á99-1Á02), and was only marginally increased in patients receiving systemic nonbiological therapy (adjusted HR 1Á06, 95% CI 1Á01-1Á12). While there was a trend towards an increased risk among patients treated with biologics, this was not statistically significant (adjusted HR 1Á62, 95% CI 0Á92-2Á87). Moreover, among patients with a history of previous depression, risk factors such as IBD and diabetes had very little impact on the risk of recurrent depression (Table S4 ; see Supporting Information).
Risk of depression in patients hospitalized due to psoriasis
In total, 5883 patients had at least one inpatient hospitalization due to psoriasis. At baseline, the mean age was 49Á1 AE 18Á4 years, and 48Á9% were women. Compared with the general population, these patients had lower education and income levels, whereas smoking, alcohol abuse and medical comorbidity occurred markedly more frequently than in the general population (Table S5 ; see Supporting Information). The IR of first-time depression per 1000 person-years was 15Á5 (95% CI 14Á5-16Á5), while the IR of recurrent depression was 416Á3 (95% CI 363Á8-476Á2). After adjustment for confounding factors, the risk of first-time depression after hospitalization due to psoriasis was slightly increased (HR 1Á23, 95% CI 1Á14-1Á33).
Discussion
In this nationwide registry-based cohort study, psoriasis managed with topical or systemic nonbiological therapy (presumably mild-to-moderate severity) was associated with a marginal increase in risk of depression after controlling for measured confounders. A somewhat higher risk was seen among patients requiring biological therapy -namely those with more severe psoriasis, and especially among patients 40-50 years of age -suggesting that these patients may represent a particularly vulnerable group in which increased awareness may be needed. The incidence of recurrent depression was increased approximately 10-fold compared with first-time depression; however, the risk of recurrent depression was not increased among patients with psoriasis compared with the general population, and neither was the risk of recurrent depression noticeably associated with severity of psoriasis. While patients qualifying for biological therapy may represent patients with the greatest psoriasis-associated impairment in quality of life, these therapies may potentially reduce this impairment by improving psoriasis. Indeed, conventional systemics and biologics have been associated with reduction in depressive symptoms in some studies, whereas others have shown conflicting results. [19] [20] [21] [22] [23] [24] Nevertheless, very recent data from Denmark suggest that even among patients treated with biologics, only very few patients have achieved a DLQI score ≤ 1 after 1 year of therapy, suggesting that the negative impact on quality of life is not completely ameliorated by use of currently approved biologics. 25 On the other hand, while hospitalized patients predominantly have severe disease, these individuals may often not wish to receive, or have certain contraindications to, systemic therapy. For these patients, hospitalization may be used as a way to achieve stabilization in patients with low adherence to treatment, such as those with a high comorbidity burden (e.g. alcohol abuse), which may be contributing to the risk of depression. Previous studies have used various definitions to examine the risk of depression in patients with psoriasis. Wu et al. 11 examined the risk of depression in patients with psoriasis using electronic medical records based in the U.S.A. After adjustment for potential confounders, the authors reported an adjusted incidence rate ratio (IRR) of 1Á14 (95% CI 1Á11-1Á17), an estimate comparable with the overall findings in our study. Notably, when stratified based on treatment patterns, patients with mild psoriasis (i.e. those receiving no treatment or topical treatment only) had a 14% increased risk of depression (adjusted IRR 1Á14, 95% CI 1Á12-1Á17), whereas patients classified as having severe psoriasis (i.e. those receiving either phototherapy, conventional systemic medication or biological therapy) had only an 8% increased risk of depression (adjusted IRR 1Á08, 95% CI 1Á01-1Á14). A previous study from Denmark 9 studied the risk of first-time depression, defined either by hospitalization for depression or by prescription of antidepressants regardless of the reason these were prescribed. The risk was found to be increased only in patients < 50 years of age with at least three hospital contacts due to psoriasis (adjusted IRR 1Á23, 95% CI 1Á03-1Á46).
Certain limitations apply to the interpretation of the present findings. Depression is a complex and multifactorial condition, and while observational studies may provide evidence of associations, such data cannot establish a causal link. Consequently, whether the slightly increased risk of depression associated with psoriasis in our study was in fact due to psoriasis itself, or whether this was due to unmeasured lifestyle factors remains unclear. Indeed, the magnitude of the association especially among patients with mild and moderate psoriasis was relatively small, and we cannot refute that this finding may be due to increased awareness of depressive symptoms among physicians.
Moreover, we lacked information on objective measures of psoriasis severity such as Psoriasis Area and Severity Index scores. Furthermore, although the severity assessment based on treatment of psoriasis has previously been validated with high accuracy, it is likely that treatment of psoriasis may have reduced the signs and symptoms of psoriasis, and any psoriasis severity-correlated risk would have been reduced as a consequence. Even patients with relatively mild psoriasis may have psoriasis in visible or highly bothersome locations (e.g. the face or genitals), which may considerably impair quality of life and, in turn, lead to depression. 26, 27 Such information would not be captured by use of pharmacotherapy, and the results should be interpreted accordingly. Lastly, the end point of depression is highly heterogeneous and may range from severe major depressive disorders requiring specialist psychiatric care to milder symptoms of depression that may be managed by general practitioners alone, and the results should be interpreted accordingly. Important strengths of the study include the sheer number of patients in the nationwide cohort, and the well-established high quality of the Danish registries whereby recall bias and loss to followup are virtually nonexistent.
In conclusion, we found an overall modest increased risk of depression in patients with psoriasis, with the highest risk occurring among middle-aged patients with severe psoriasis and the highest incidence among those with a prior history of depression. These results may help clinicians identify which patients are at particularly high risk of depression, in whom pre-emptive measures may be needed to reduce the future risk of depression.
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